United Kingdom UK: Cause of Death: by Communicable Diseases & Maternal, Prenatal & Nutrition Conditions: % of Total data was reported at 7.700 % in 2016. This records a decrease from the previous number of 8.000 % for 2015. United Kingdom UK: Cause of Death: by Communicable Diseases & Maternal, Prenatal & Nutrition Conditions: % of Total data is updated yearly, averaging 7.850 % from Dec 2000 (Median) to 2016, with 4 observations. The data reached an all-time high of 11.800 % in 2000 and a record low of 7.300 % in 2010. United Kingdom UK: Cause of Death: by Communicable Diseases & Maternal, Prenatal & Nutrition Conditions: % of Total data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s United Kingdom – Table UK.World Bank.WDI: Health Statistics. Cause of death refers to the share of all deaths for all ages by underlying causes. Communicable diseases and maternal, prenatal and nutrition conditions include infectious and parasitic diseases, respiratory infections, and nutritional deficiencies such as underweight and stunting.; ; Derived based on the data from WHO's Global Health Estimates.; Weighted average;

Notifiable infectious disease statistics Source agency: ISD Scotland (part of NHS National Services Scotland) Designation: National Statistics Language: English Alternative title: Notifiable infectious disease statistics

Legacy unique identifier: P00478

United Kingdom UK: Cause of Death: by Non-Communicable Diseases: % of Total data was reported at 88.800 % in 2016. This records an increase from the previous number of 88.600 % for 2015. United Kingdom UK: Cause of Death: by Non-Communicable Diseases: % of Total data is updated yearly, averaging 88.700 % from Dec 2000 (Median) to 2016, with 4 observations. The data reached an all-time high of 89.300 % in 2010 and a record low of 85.000 % in 2000. United Kingdom UK: Cause of Death: by Non-Communicable Diseases: % of Total data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s United Kingdom – Table UK.World Bank.WDI: Health Statistics. Cause of death refers to the share of all deaths for all ages by underlying causes. Non-communicable diseases include cancer, diabetes mellitus, cardiovascular diseases, digestive diseases, skin diseases, musculoskeletal diseases, and congenital anomalies.; ; Derived based on the data from WHO's Global Health Estimates.; Weighted average;

This statistic depicts the proportion of the adult population in the United Kingdom with an infectious disease in 2018, by age. In the UK, six percent of the total population have been diagnosed with an infectious disease, although ten percent of respondents reported having an infectious disease.

Communicable Disease Reports (CDR) - Voluntary laboratory reporting (ROCR, Review of Central Returns, Lite licence pending)

Forecast: Total Number of Scientific Publications in Infectious Diseases in the UK 2022 - 2026 Discover more data with ReportLinker!

Objectives: To assess the percentage of people in the UK with cough, fever or loss of taste or smell who have not had a positive COVID-19 test result who had been to work, to shops, socialised or provided care to a vulnerable person in the 10 days after developing symptoms. To investigate whether these rates differed according to the type of symptom, what the participant thought the cause of their symptoms was and whether they had taken a COVID-19 test.Design: Four online cross-sectional surveys using non-probability quota sampling method (n=8547).Setting: Data were collected across the UK from 20 September to 3 November 2021, via a market research company.Participants: Aged over 16 years living in the UK.Primary outcome measures: Out-of-home activity.Results: 498 participants reported one or more symptoms and had not had a positive COVID-19 test result. Within that group, about half of employed participants had attended work while symptomatic (51.2%-56.3% depending on the symptom, 95% CIs 42.2% to 65.6%). Rates of other contact behaviours ranged from 31.4% (caring for a vulnerable person after developing a cough: 95% CI 24.3% to 38.4%) to 61.5% (shopping for groceries or pharmacy after developing a cough: 95% CI 54.1% to 68.9%). There were no differences according to type of symptom experienced or what the participant felt might be the cause. People who had taken a COVID-19 test were less likely to go out shopping for non-essentials than people who had not taken a test.Conclusion: Many people in the UK with symptoms of an infectious disease were not following government advice to stay at home if they believed they had an infectious illness. Reducing these rates may require a shift in our national attitude to the acceptability of people attending work with infectious illnesses.

Deaths from infectious and parasitic disease . Directly age-Standardised Rates (DSR) per 100,000 population Source: Office for National Statistics (ONS) Publisher: Information Centre (IC) - Clinical and Health Outcomes Knowledge Base Geographies: Local Authority District (LAD), Government Office Region (GOR), National, Strategic Health Authority (SHA) Geographic coverage: England Time coverage: 2005-07, 2007 Type of data: Administrative data

Cumulative figures of notifications of infectious diseases reported to the Public Health Agency Duty Room

This statistic displays the results of a survey asking individuals in the United Kingdom whether they believe that vaccines are effective in preventing infectious diseases in 2019. According to the results, ** percent of respondents definitely believe that vaccines are effective in preventing disease, while only ***** percent of respondents are do not believe in vaccines to some extent.

Forecast: Share of Scientific Publications Involving International Collaboration in Infectious Diseases in the UK 2022 - 2026 Discover more data with ReportLinker!

Legacy unique identifier: P00476

Snapshot img

Infectious Disease Market Size 2025-2029

The infectious disease market size is forecast to increase by USD 160.8 billion at a CAGR of 14.7% between 2024 and 2029.

The market is experiencing significant growth due to the rising prevalence of bacterial diseases such as Clostridium and Staphylococcus, which necessitate advanced diagnostics. Immunodiagnostics and next-generation sequencing (NGS) are emerging as key technologies in infectious disease diagnostics, offering faster and more accurate results than traditional methods. The development of novel drugs for tuberculosis (TB) and sepsis is another growth driver, as is the increasing demand for molecular diagnostics. However, the market faces challenges such as the adverse effects of generic drugs and the high cost of developing new anti-infective drugs. The use of NGS in infectious disease diagnostics is a major trend, enabling the identification of multiple pathogens in a single test and facilitating personalized treatment plans.
In summary, the market is driven by the rising prevalence of infectious diseases, the development of novel drugs, and the adoption of advanced diagnostics, but is challenged by the high cost of drug development and the adverse effects of generic drugs. Immunodiagnostics and NGS are key technologies driving market growth.

What will be the Size of the Infectious Disease Market During the Forecast Period?

Request Free Sample

The market encompasses diagnostic tools and technologies designed to promptly identify various pathogens, including bacteria, viruses, and parasites. This market is driven by the urgent need for accurate and rapid results in diverse healthcare settings, such as point-of-care diagnostic testing in urgent care centers, emergency rooms, and ambulances. The importance of infectious disease diagnostics extends beyond healthcare facilities, as personal health and infection control are increasingly prioritized in everyday life. 
Market dynamics are influenced by several factors, including inadequate infrastructure and poor water sanitation in certain regions, which contribute to the spread of infectious diseases. The ongoing demand for improved patient outcomes necessitates the development of advanced diagnostic technologies, such as immunodiagnostics, clinical microbiology, DNA sequencing, next-generation sequencing (NGS), DNA microarray, and various tests for diseases like hepatitis, syphilis, mosquito-borne diseases, gonorrhea, and RNA viruses.
Healthcare professionals are under constant pressure to provide accurate diagnoses and implement effective infection control measures. As a result, there is a growing emphasis on training and education to ensure the proper use and interpretation of diagnostic tools. The market is expected to continue growing as the global population's healthcare needs evolve and advancements in diagnostics technology are made.

How is this Infectious Disease Industry segmented and which is the largest segment?

The industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Product

  Drugs
  Vaccines


End-user

  Hospital
  Multispecialty clinic
  Others


Type

  Bacterial infections
  Viral infections
  Fungal infections
  Parasitic infections


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK
    France
    Italy


  Asia

    China
    India
    Japan


  Rest of World (ROW)

By Product Insights

The drugs segment is estimated to witness significant growth during the forecast period. The market is driven by several key factors, including increasing government initiatives and non-profit organization efforts, the prevalence of various infectious diseases, and rising research and development funding. Infectious diseases such as influenza, giardiasis, HIV/AIDS, mononucleosis, and the common cold continue to pose a significant health concern. Point-of-care diagnostic testing, which offers rapid results and prompt diagnosis, is increasingly being adopted in urgent care centers, emergency rooms, ambulances, and physician offices. Inadequate infrastructure, poor water sanitation, and lack of training for healthcare professionals remain challenges in controlling the spread of infectious diseases. Pathogens such as bacteria, viruses, fungi, and parasites can cause respiratory diseases, hospital-acquired infections, sexually transmitted infections, and mosquito-borne diseases.

Technologies like chest X-rays, CT scans, physical exams, laboratory tests, PCR testing, and immunodiagnostics are used for diagnosis. Infection control, personal health, hygiene, and preventative healthcare are essential to mitigate the impact of infectious diseases. The market for infectious disease diagnostics includes kits, cons

This is a mixed methods study, comprising both qualitative and quantitative data. The aim of this study was to determine how risk associated with infections and the control of infectious diseases were managed and distributed in the NHS quasi market, the specific objectives were:
1. to evaluate the effectiveness of formal contracts, regulations and informal practices relating to risks of infection and the likely effectiveness of these clauses;
2. to consider how agency relationships within professional and managerial systems affect the implementation of programmes to reduce risk and cope with outbreaks of infections;
3. to consider how contracting agents perceive risks associated with infectious disease and the values placed on risk avoidance practices compared with preventive practices;
4. to consider how risk, financial, social and psychological, are distributed amongst NHS agencies, other agencies, patients and families; to consider how initial allocation of risk in the contracting process affects the eventual distribution of this burden; and consider attempts to pool risks.
Objectives 1-3 were achieved in full. In objective four, distribution of risks amongst NHS agencies and budgets arising from unforeseen events and allocation of risks in contracts is addressed. But risks to patients and their families was not possible due to logistical difficulties and resistance from Trusts to approaching infected patients. The objective was revised to include a survey of all outbreaks reported six months following site visits.

IntroductionPublic health mitigation policies aimed at slowing the spread of COVID-19 led to an increase in mental health problems (MHPs). This study examines the association between multiple pre-pandemic health behaviors and MHPs prior to, and during, the COVID-19 pandemic.MethodsWe analyzed a representative population sample of 11,256 adults (aged 20–65 years) from Understanding Society—The UK Household Longitudinal Study. Baseline data from participants interviewed in 2017/2019 (wave 9) were linked to web surveys conducted during the COVID-19 pandemic. We used latent class analysis (LCA) to identify mutually exclusive health behavior (physical activity, alcohol consumption, eating habits and smoking tobacco) clusters by gender, and examined the sociodemographic correlates of each cluster. We assessed how pre-pandemic latent classes of health behaviors were associated with changes in MHPs during the pandemic using fixed effects regression models.ResultsThree health behavior clusters were identified: positive (33%), moderate (24%), and high risk (43%), where similar behaviors clustered within individuals and sociodemographic circumstances. In particular, gender, age, migrant status and ethnicity were found to have strong associations with each cluster. Our results also demonstrated a clear association in MHPs with health behaviors both prior to, and during the pandemic. There were significant increases in MHPs between 2017/2019 and January 2021, with fluctuations coinciding with changes in public health mitigation policies. Assessments across the three clusters showed about 25.2%, 16.9%, and 0.7% increases in MHPs in the positive, moderate and high risk health behavior clusters, respectively.DiscussionThis study shows that pre-pandemic health behaviors were significantly associated with mental health before and during the pandemic. Holistic policy interventions and promotions targeting multiple health behaviors may be an effective strategy to improve mental health in the pandemic recovery period.

Infectious disease is the single biggest cause of death worldwide. New infectious agents require investigation to understand its characteristics and how infection with this pathogen results in a disease process. We need to understand risk factors for severe illness and how to best treat disease caused by this pathogen. In order to develop a mechanistic understanding of disease processes, such that risk factors for severe illness can be identified and treatments can be developed, it is necessary to understand pathogen characteristics associated with virulence, the replication dynamics and in-host evolution of the pathogen, the dynamics of the host response, the pharmacology of antimicrobial or host-directed therapies, the transmission dynamics, and factors underlying individual susceptibility. This study is designed for the rapid, coordinated clinical investigation of patients with confirmed infection with a pathogen of public interest. The study has been designed to maximize the likelihood that as much data as possible is collected and shared rapidly in a format that can be easily aggregated, tabulated and analysed across many different settings globally. The study is designed to have some level of flexibility in order to ensure the broadest acceptance.

IntroductionCost-effective interventions that improve medication adherence are urgently needed to address the epidemic of non-communicable diseases (NCDs) in India. However, in low- and middle-income countries like India, there is a lack of analysis evaluating the effectiveness of adherence improving strategies. We conducted the first systematic review evaluating interventions aimed at improving medication adherence for chronic diseases in India.MethodsA systematic search on MEDLINE, Web of Science, Scopus, and Google Scholar was conducted. Based on a PRISMA-compliant, pre-defined methodology, randomized control trials were included which: involved subjects with NCDs; were located in India; used any intervention with the aim of improving medication adherence; and measured adherence as a primary or secondary outcome.ResultsThe search strategy yielded 1,552 unique articles of which 22 met inclusion criteria. Interventions assessed by these studies included education-based interventions (n = 12), combinations of education-based interventions with regular follow up (n = 4), and technology-based interventions (n = 2). Non-communicable diseases evaluated commonly were respiratory disease (n = 3), type 2 diabetes (n = 6), cardiovascular disease (n = 8) and depression (n = 2).ConclusionsAlthough the vast majority of primary studies supporting the conclusions were of mixed methodological quality, patient education by CHWs and pharmacists represent promising interventions to improve medication adherence, with further benefits from regular follow-up. There is need for systematic evaluation of these interventions with high quality RCTs and their implementation as part of wider health policy.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022345636, identifier: CRD42022345636.

At the end of 2022 and beginning of 2023, weekly reported cases of scarlet fever had been significantly higher in England compared to the same weeks in the preceding five years. In week 49 of the 2022/23 season, over 10 thousand cases were reported compared to only 79 in the year prior. Bacteria belonging to group A streptococcus (more commonly called Strep A) causes scarlet fever, and, while it is highly infectious, usually only causes mild illness.